Myasthenia gravis and acetylcholine receptor. Effect of steroids in clinical course and cellular immune response to acetylcholine receptor.

Lymphocytes from patients with myasthenia gravis (MG) were transformed when cultured in vitro with an acetylcholine receptor fraction extracted from the electric organ of an electric eel. Marked diminution of the cellular response to acetylcholine was shown in patients who improved clinically with prednisone treatment. The transient clinical deterioration during the first days of prednisone treatment was accompanied by a transient increase in lymphocyte response. These findings that an in vivo sensitization of lymphocytes to self-acetylcholine receptor may occur in MG, and that a cell-mediated autoimmune mechanism may be important in the pathogenesis of the neuromuscular block. The present observations indicate that prednisone provides a measure of immunosuppression in MG. The transient clinical deterioration during the first days of prednisone therapy may reflect an enhancement of cell reactivity by this drug.

[1]  I. Silman,et al.  Preparation and immunochemical characterization of a water-soluble acetylcholine receptor fraction from the electric organ tissue of the electric eel. , 1975, Immunochemistry.

[2]  I. Cohen,et al.  STIMULATION OF RAT LYMPHOCYTE PROLIFERATION BY HYDROCORTISONE DURING THE INDUCTION OF CELL-MEDIATED IMMUNITY IN VITRO , 1974, Transplantation.

[3]  D. Drachman,et al.  Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment. , 1974, The New England journal of medicine.

[4]  D. Drachman,et al.  Neuromuscular Junction in Myasthenia Gravis: Decreased Acetylcholine Receptors , 1973, Science.

[5]  R. Nowak,et al.  Thymic lymphocyte function in myasthenia gravis , 1973, Neurology.

[6]  J. Changeux,et al.  Immunological characterisation of the cholinergic receptor protein from Electrophorus electricus. , 1973, FEBS letters.

[7]  E. Kott,et al.  Myasthenia gravis , 1973, Neurology.

[8]  J. Patrick,et al.  Autoimmune Response to Acetylcholine Receptor , 1973, Science.

[9]  G. Genkins,et al.  Leukocyte response to muscle antigens in myasthenia gravis , 1973, Neurology.

[10]  S. Kawanami,et al.  Destruction of cultured thymus cells by autologous lymphocytes from a patient with myasthenia gravis. , 1973, Lancet.

[11]  P. Kornfeld,et al.  Studies in myasthenia gravis: cellular hypersensitivity to skeletal muscle. , 1972, American journal of clinical pathology.

[12]  D. Grob,et al.  Corticosteroids in management of severe, generalized myasthenia gravis , 1972, Neurology.

[13]  R. Jenkins.  Treatment of myasthenia gravis with prednisone. , 1972, Lancet.

[14]  W. Engel,et al.  Benefit from alternate-day prednisone in myasthenia gravis. , 1972, The New England journal of medicine.

[15]  G. Genkins,et al.  Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. , 1971, The Mount Sinai journal of medicine, New York.

[16]  P. Kornfeld,et al.  Studies in myasthenia gravis: biologic aspects. , 1971, The Mount Sinai journal of medicine, New York.

[17]  Y. London.  Ox peripheral nerve myelin membrane. Purification and partial characterization of two basic proteins. , 1971, Biochimica et biophysica acta.

[18]  D. Grob,et al.  Corticotrophin therapy in myasthenia gravis , 1971, Neurology.

[19]  D. Grob,et al.  THE USE OF ACTH AND CORTICOSTEROIDS IN MYASTHENIA GRAVIS , 1971, Annals of the New York Academy of Sciences.

[20]  M. Kjær.  MYASTHENIA GRAVIS AND MYASTHENIC SYNDROMES TREATED WITH PREDNISONE , 1971 .

[21]  V. Lennon,et al.  Immunopharmacological disease: a break in tolerance to receptor sites. , 1971, Lancet.

[22]  M. Kjaer,et al.  Continuous treatment of myasthenia gravis with prednisone. , 1971, Lancet.

[23]  W. Engel,et al.  ALTERNATE-DAY PREDNISONE IN A PATIENT WITH MYASTHENIA GRAVIS , 1970 .

[24]  I. Cohen,et al.  Glucocorticoids and cellular immunity in vitro. Facilitation of the sensitization phase and inhibition of the effector phase of a lymphocyte anti-fibroblast reaction. , 1970 .

[25]  M. Sela,et al.  Basic encephalitogenic protein: A simplified purification on sulphoethyl‐sephadex , 1970, FEBS letters.

[26]  A. J. Strauss,et al.  Myasthenia gravis. Immunological relationship between striated muscle and thymus. , 1966, Lancet.

[27]  G. Cage,et al.  FURTHER STUDIES ON THE SPECIFICITY OF PRESUMED IMMUNE ASSOCIATIONS OF MYASTHENIA GRAVIS AND CONSIDERATION OF POSSIBLE PATHOGENIC IMPLICATIONS , 1966, Annals of the New York Academy of Sciences.

[28]  G. Matell,et al.  TREATMENT OF SEVERE MYASTHENIA GRAVIS WITH LARGE DOSES OF ACTH , 1966, Annals of the New York Academy of Sciences.

[29]  J. Simpson,et al.  MYASTHENIA GRAVIS AS AN AUTOIMMUNE DISEASE: CLINICAL ASPECTS , 1966, Annals of the New York Academy of Sciences.

[30]  H. Oosterhuis,et al.  MULTIPLE ANTIBODY PRODUCTION IN MYASTHENIA GRAVIS. , 1963, Lancet.

[31]  E. Beutner,et al.  Studies on autoantibodies in myasthenia gravis. , 1962, JAMA.

[32]  J. Simpson.  Myasthenia Gravis: A New Hypothesis , 1960 .

[33]  S. Fuchs,et al.  Cellular immune response to acetylcholine receptor-rich fraction, in patients with myasthenia gravis. , 1975, Clinical and experimental immunology.

[34]  Z. Hall.  Release of neurotransmitters and their interaction with receptors. , 1972, Annual review of biochemistry.

[35]  F. Valentine.  27 – LYMPHOCYTE TRANSFORMATION: THE PROLIFERATION OF HUMAN BLOOD LYMPHOCYTES STIMULATED BY ANTIGEN IN VITRO , 1971 .